TY - JOUR
T1 - Venous thromboembolism in patients discharged after COVID-19 hospitalization
AU - Engelen, Matthias M.
AU - Vandenbriele, Christophe
AU - Balthazar, Tim
AU - Claeys, Eveline
AU - Gunst, Jan
AU - Guler, Ipek
AU - Jacquemin, Marc
AU - Janssens, Stefan
AU - Lorent, Natalie
AU - Liesenborghs, Laurens
AU - Peerlinck, Kathelijne
AU - Pieters, Griet
AU - Rex, Steffen
AU - Sinonquel, Pieter
AU - Van der Linden, Lorenz
AU - Van Laer, Christine
AU - Vos, Robin
AU - Wauters, Joost
AU - Wilmer, Alexander
AU - Verhamme, Peter
AU - Vanassche, Thomas
N1 - NPP; OGOA
PY - 2021
Y1 - 2021
N2 - Background Venous thromboembolism (VTE) is a frequent complication of COVID-19, so that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with COVID-19 is well established. However, the incidence of VTE after discharge and whether postdischarge thromboprophylaxis is beneficial and safe are unclear. In this prospective observational single-center study, we report the incidence of VTE 6 weeks after hospitalization and the use of postdischarge thromboprophylaxis.Methods Patients hospitalized with confirmed COVID-19 were invited to a multidisciplinary follow-up clinic 6 weeks after discharge. D-dimer and C-reactive protein were measured, and all patients were screened for deep vein thrombosis with venous duplex-ultrasound. Additionally, selected high-risk patients received computed tomography pulmonary angiogram or ventilation-perfusion (V/Q) scan to screen for incidental pulmonary embolism.Results Of 485 consecutive patients hospitalized from March through June 2020, 146 patients were analyzed, of which 39% had been admitted to the intensive care unit (ICU). Postdischarge thromboprophylaxis was prescribed in 28% of patients, but was used more frequently after ICU stay (61%) and in patients with higher maximal D-dimer and C-reactive protein levels during hospitalization. Six weeks after discharge, elevated D-dimer values were present in 32% of ward and 42% of ICU patients. Only one asymptomatic deep vein thrombosis (0.7%) and one symptomatic pulmonary embolism (0.7%) were diagnosed with systematic screening. No bleedings were reported.Conclusion In patients who had been hospitalized with COVID-19, systematic screening for VTE 6 weeks after discharge revealed a low incidence of VTE. A strategy of selectively providing postdischarge thromboprophylaxis in high-risk patients seems safe and potentially effective.
AB - Background Venous thromboembolism (VTE) is a frequent complication of COVID-19, so that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with COVID-19 is well established. However, the incidence of VTE after discharge and whether postdischarge thromboprophylaxis is beneficial and safe are unclear. In this prospective observational single-center study, we report the incidence of VTE 6 weeks after hospitalization and the use of postdischarge thromboprophylaxis.Methods Patients hospitalized with confirmed COVID-19 were invited to a multidisciplinary follow-up clinic 6 weeks after discharge. D-dimer and C-reactive protein were measured, and all patients were screened for deep vein thrombosis with venous duplex-ultrasound. Additionally, selected high-risk patients received computed tomography pulmonary angiogram or ventilation-perfusion (V/Q) scan to screen for incidental pulmonary embolism.Results Of 485 consecutive patients hospitalized from March through June 2020, 146 patients were analyzed, of which 39% had been admitted to the intensive care unit (ICU). Postdischarge thromboprophylaxis was prescribed in 28% of patients, but was used more frequently after ICU stay (61%) and in patients with higher maximal D-dimer and C-reactive protein levels during hospitalization. Six weeks after discharge, elevated D-dimer values were present in 32% of ward and 42% of ICU patients. Only one asymptomatic deep vein thrombosis (0.7%) and one symptomatic pulmonary embolism (0.7%) were diagnosed with systematic screening. No bleedings were reported.Conclusion In patients who had been hospitalized with COVID-19, systematic screening for VTE 6 weeks after discharge revealed a low incidence of VTE. A strategy of selectively providing postdischarge thromboprophylaxis in high-risk patients seems safe and potentially effective.
KW - C-Reactive Protein/metabolism
KW - COVID-19/blood
KW - Fibrin Fibrinogen Degradation Products/metabolism
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Patient Discharge
KW - Prospective Studies
KW - Pulmonary Embolism/blood
KW - SARS-CoV-2/metabolism
KW - Venous Thromboembolism/blood
KW - Venous Thrombosis/blood
U2 - 10.1055/s-0041-1727284
DO - 10.1055/s-0041-1727284
M3 - A1: Web of Science-article
C2 - 33893631
SN - 0094-6176
VL - 47
SP - 362
EP - 371
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
IS - 4
ER -